血浆亚精胺浓度作为人类骨髓瘤治疗反应的早期指标。
Plasma spermidine concentrations as early indication of response to therapy in human myeloma.
作者信息
Van Dobbenburgh O A, Houwen B, Jurjens H, Marrink J, Halie M R, Nieweg H O
出版信息
J Clin Pathol. 1983 Jul;36(7):804-7. doi: 10.1136/jcp.36.7.804.
Eighteen patients with melphalan refractory myeloma were treated with vindesine and prednisone. Plasma spermidine concentrations were measured by radioimmunoassay before and after a single vindesine injection. Seven patients showed a significant rise of plasma spermidine after vindesine and five of these showed a clinical response on further evaluation. Of the 11 patients who did not show raised spermidine concentrations, 10 did not respond to the therapy. The correlation between clinical response/rise of spermidine and between non-response/no rise of spermidine was statistically significant (p less than 0.05). Pretreatment spermidine concentrations did not distinguish those who responded to treatment nor did they differ in patients and controls.
18例美法仑难治性骨髓瘤患者接受了长春地辛和泼尼松治疗。单次注射长春地辛前后，采用放射免疫分析法测定血浆亚精胺浓度。7例患者注射长春地辛后血浆亚精胺显著升高，其中5例在进一步评估时有临床反应。在11例血浆亚精胺浓度未升高的患者中，10例对治疗无反应。临床反应/亚精胺升高与无反应/亚精胺未升高之间的相关性具有统计学意义（p<0.05）。治疗前亚精胺浓度无法区分对治疗有反应的患者，患者与对照组之间也无差异。
Zotero 插件